Evoke Pharma (NASDAQ:EVOK) issued its quarterly earnings data on Tuesday. The specialty pharmaceutical company reported ($0.09) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.08) by ($0.01), Bloomberg Earnings reports.

Shares of EVOK opened at $2.74 on Wednesday. The firm has a market capitalization of $46.47 million, a P/E ratio of -3.30 and a beta of 1.66. Evoke Pharma has a one year low of $1.85 and a one year high of $3.40.

In related news, major shareholder Lvp Gp Iii, Llc bought 500,000 shares of the stock in a transaction that occurred on Monday, August 20th. The shares were bought at an average cost of $2.35 per share, for a total transaction of $1,175,000.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 11.94% of the stock is currently owned by insiders.

A hedge fund recently bought a new stake in Evoke Pharma stock. JPMorgan Chase & Co. bought a new stake in shares of Evoke Pharma Inc (NASDAQ:EVOK) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 37,323 shares of the specialty pharmaceutical company’s stock, valued at approximately $111,000. JPMorgan Chase & Co. owned approximately 0.22% of Evoke Pharma as of its most recent filing with the Securities and Exchange Commission (SEC). 18.71% of the stock is owned by institutional investors.

EVOK has been the subject of several research analyst reports. ValuEngine raised Evoke Pharma from a “sell” rating to a “hold” rating in a report on Thursday, August 2nd. HC Wainwright set a $9.00 price objective on Evoke Pharma and gave the stock a “buy” rating in a report on Friday, August 17th. Finally, Zacks Investment Research raised Evoke Pharma from a “hold” rating to a “buy” rating and set a $2.75 price objective for the company in a report on Friday, August 17th.

WARNING: This story was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this story on another website, it was copied illegally and reposted in violation of US & international trademark and copyright legislation. The original version of this story can be accessed at https://www.thecerbatgem.com/2018/11/14/evoke-pharma-evok-releases-quarterly-earnings-results-misses-expectations-by-0-01-eps.html.

About Evoke Pharma

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray, which is in Phase 2b clinical trials for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.

Recommended Story: Dividend Aristocrat Index

Earnings History for Evoke Pharma (NASDAQ:EVOK)

Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.